MacroGenics
Clinical trials sponsored by MacroGenics, explained in plain language.
MacroGenics
MGNX
NASDAQ
Biopharmaceutical company developing antibody-based cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Antibody-Drug conjugate targets Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New hope for tough blood cancers: experimental drug MGD024 enters human testing Results expected Nov 2026 (estimated)
- New drug lorigerlimab takes on Platinum-Resistant ovarian cancer Results expected Jul 2027 (estimated)